© 2009

Drug Resistance in Cancer Cells

  • Zahid H. Siddik
  • Kapil Mehta

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Gergely Szakács, Kenneth Kin Wah (To), Orsolya Polgár, Robert W. Robey, Susan E. Bates
    Pages 1-20
  3. Dominic Fan, Sun-Jin Kim, Robert L. Langley, Isaiah J. Fidler
    Pages 21-52
  4. Tomohisa Yokoyama, Yasuko Kondo, Oliver Bögler, Seiji Kondo
    Pages 53-71
  5. Stacey J. Baker, E. Premkumar Reddy
    Pages 73-93
  6. P.S. Hodkinson, Tariq Sethi
    Pages 115-135
  7. Dunyaporn Trachootham, Wan Zhang, Peng Huang
    Pages 137-175
  8. Ajaikumar B. Kunnumakkara, Preetha Anand, Bharat B. Aggarwal
    Pages 177-208
  9. Bulent Ozpolat
    Pages 233-255
  10. Elisa Barbarotto, George A. Calin
    Pages 257-270
  11. Melissa A. Troester, Jason I. Herschkowitz, Katherine A. Hoadley
    Pages 271-294
  12. Natalie Charnley, Catharine West, Pat Price
    Pages 295-313
  13. Marion M. Chan, Dunne Fong
    Pages 315-342
  14. Back Matter
    Pages 343-363

About this book


An estimated 1.5 million patients in the United States are diagnosed with cancer every year and over half-a-million individuals die of the disease. Since the vast majority of the deaths occur after medical intervention with anticancer therapy, both conventional chemotherapy and novel targeted therapy, it can be concluded that these patients die from drug resistant cancers. A growing number of studies have revealed that mechanisms underlying the development of drug resistance in cancer cells are manifold and complex and very likely are dependent on cell and microenvironment context. In view of these facts, it is important to document the mechanisms of drug resistance and understand which are the dominant resistance pathways in a particular tumor type that could provide potential therapeutic targets in a clinical setting.
This book serves as a single source for the current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance. Comprehensive reviews written by renowned experts provide great insight on the current knowledge on drug resistance mechanisms. This book is a ready source of information to clinicians, cell and cancer biologists and defines molecular drug resistance mechanisms that are challenging scientists and clinical oncologists today.

About Editors:
Dr. Kapil Mehta is a Professor in the Department of Experimental Therapeutics, The University of Texas M. D Anderson Cancer Center, Houston, TX. He has published widely and received several patents on novel discoveries relating to drug resistance in the field of cancer therapeutics.
Dr. Zahid H. Siddik is also a Professor in the Department of Experimental Therapeutics at The University of Texas M.D. Anderson Cancer Center. He has studied extensively the mechanisms of drug action and resistance, and is recognized for his seminal studies with platinum-based antitumor agents.


apoptosis cancer cancer therapy cell chemoresistance cytokine cytokines drug drug design drug resistance imaging metastasis resistance tissue tumor

Editors and affiliations

  • Zahid H. Siddik
  • Kapil Mehta

There are no affiliations available

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods